These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
144 related articles for article (PubMed ID: 7544745)
21. A prospective trial of prenatal screening for Down syndrome by means of maternal serum alpha-fetoprotein, human chorionic gonadotropin, and unconjugated estriol. Burton BK; Prins GS; Verp MS Am J Obstet Gynecol; 1993 Sep; 169(3):526-30. PubMed ID: 7690522 [TBL] [Abstract][Full Text] [Related]
22. Elevated maternal urine level of beta-core fragment of human chorionic gonadotropin versus serum triple test in the second-trimester detection of down syndrome. Bahado-Singh R; Oz U; Rinne K; Hunter D; Cole L; Mahoney MJ; Baumgarten A Am J Obstet Gynecol; 1999 Oct; 181(4):929-33. PubMed ID: 10521756 [TBL] [Abstract][Full Text] [Related]
23. [The biochemical screening of Down's syndrome]. Beolchi S; Fadin M; Paganelli A; Brambilla CI; Messina C; Morandi C Minerva Ginecol; 1995; 47(7-8):315-8. PubMed ID: 8559442 [TBL] [Abstract][Full Text] [Related]
24. Reducing the need for amniocentesis in women 35 years of age or older with serum markers for screening. Haddow JE; Palomaki GE; Knight GJ; Cunningham GC; Lustig LS; Boyd PA N Engl J Med; 1994 Apr; 330(16):1114-8. PubMed ID: 7510852 [TBL] [Abstract][Full Text] [Related]
26. Multiple-marker screening in pregnancies with hydropic and nonhydropic Turner syndrome. Saller DN; Canick JA; Schwartz S; Blitzer MG Am J Obstet Gynecol; 1992 Oct; 167(4 Pt 1):1021-4. PubMed ID: 1384332 [TBL] [Abstract][Full Text] [Related]
27. Maternal serum screening for alpha-fetoprotein, unconjugated estriol, and human chorionic gonadotropin between 11 and 15 weeks of pregnancy to detect fetal chromosome abnormalities. Crandall BF; Hanson FW; Keener S; Matsumoto M; Miller W Am J Obstet Gynecol; 1993 Jun; 168(6 Pt 1):1864-7; discussion 1867-9. PubMed ID: 7686337 [TBL] [Abstract][Full Text] [Related]
28. [Prenatal maternal blood screening for the detection of fetal chromosomal abnormalities: clinical importance of the rate of false positives]. Alvarez-Nava F; Soto M; Padrón T; Morales A; Villalobos D; Rojas de Atencio A; Prieto M; Martínez MC Invest Clin; 2003 Sep; 44(3):195-207. PubMed ID: 14552058 [TBL] [Abstract][Full Text] [Related]
29. [Prenatal diagnosis. Review, personal and prospective studies]. Engel E; Empson J; DeLozier D; McGee B; da Costa Woodson E; Engel-de Montmollin M; Carter T; Lorber C; Cassidy SB; Millis J; Heller RM; Boehm F; Vanhooydonk J Schweiz Med Wochenschr; 1979 Jul; 109(27):998-1010. PubMed ID: 88763 [TBL] [Abstract][Full Text] [Related]
30. Maternal serum analyte levels after first-trimester multifetal pregnancy reduction. Shulman LP; Phillips OP; Cervetti TA Am J Obstet Gynecol; 1996 Mar; 174(3):1072-4. PubMed ID: 8633639 [TBL] [Abstract][Full Text] [Related]
31. Role of prenatal ultrasonography in women with positive screen for Down syndrome on the basis of maternal serum markers. Nyberg DA; Luthy DA; Cheng EY; Sheley RC; Resta RG; Williams MA Am J Obstet Gynecol; 1995 Oct; 173(4):1030-5. PubMed ID: 7485289 [TBL] [Abstract][Full Text] [Related]
32. Screening for fetal chromosomal abnormalities by maternal serum biochemistry and ultrasound examination of fetal morphology. Hecher K; Snijders R; Nicolaides K Curr Opin Obstet Gynecol; 1993 Apr; 5(2):170-8. PubMed ID: 7683916 [TBL] [Abstract][Full Text] [Related]
33. Efficacy of maternal serum screening in the prenatal detection of fetal chromosome abnormalities in Japanese women. Kishida T; Hoshi N; Hattori R; Negishi H; Yamada H; Okuyama K; Hanatani K; Takagi T; Sagawa T; Fujimoto S Fetal Diagn Ther; 2000; 15(2):112-7. PubMed ID: 10720877 [TBL] [Abstract][Full Text] [Related]
34. Second-trimester maternal serum marker screening: maternal serum alpha-fetoprotein, beta-human chorionic gonadotropin, estriol, and their various combinations as predictors of pregnancy outcome. Yaron Y; Cherry M; Kramer RL; O'Brien JE; Hallak M; Johnson MP; Evans MI Am J Obstet Gynecol; 1999 Oct; 181(4):968-74. PubMed ID: 10521763 [TBL] [Abstract][Full Text] [Related]
35. New Down syndrome screening algorithm: ultrasonographic biometry and multiple serum markers combined with maternal age. Bahado-Singh RO; Oz AU; Kovanci E; Deren O; Copel J; Baumgarten A; Mahoney J Am J Obstet Gynecol; 1998 Dec; 179(6 Pt 1):1627-31. PubMed ID: 9855608 [TBL] [Abstract][Full Text] [Related]
36. The detection of non-immune hydrops through second-trimester maternal serum screening. Saller DN; Canick JA; Oyer CE Prenat Diagn; 1996 May; 16(5):431-5. PubMed ID: 8844001 [TBL] [Abstract][Full Text] [Related]
37. A negative second trimester triple test and absence of specific ultrasonographic markers may decrease the need for genetic amniocentesis in advanced maternal age by 60%. Rosen DJ; Kedar I; Amiel A; Ben-Tovim T; Petel Y; Kaneti H; Tohar M; Fejgin MD Prenat Diagn; 2002 Jan; 22(1):59-63. PubMed ID: 11810653 [TBL] [Abstract][Full Text] [Related]
38. [Triple test: problem or enhancement of prenatal diagnosis]. Rauskolb R; Engel W Z Geburtshilfe Neonatol; 1995; 199(3):91. PubMed ID: 7553260 [No Abstract] [Full Text] [Related]
39. Elevated maternal serum alpha-fetoprotein with low unconjugated estriol and the risk for lethal perinatal outcome. Benn PA; Craffey A; Horne D; Ramsdell L; Rodis JF J Matern Fetal Med; 2000; 9(3):165-9. PubMed ID: 10914624 [TBL] [Abstract][Full Text] [Related]
40. Multiple screening for fetal Down's syndrome with the classic triple test, dimeric inhibin A and ultrasound. Debiève F; Bouckaert A; Hubinont C; Thomas K Gynecol Obstet Invest; 2000; 49(4):221-6. PubMed ID: 10828702 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]